Skip to main content

IMAGEN MOLECULAR DE GLIOMA DE ALTO GRADO PARA LA MEJORA DE LA RESPUESTA AL TRATAMIENTO

SAF2014-52332-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images

  • Wu, Shuang|||0000-0001-7618-5476
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Villamañán de Santiago, Lucía|||0000-0002-6702-2103
  • Arias-Ramos, Nuria|||0000-0001-8983-6362
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Ortega-Martorell, Sandra|||0000-0001-9927-3209
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy. Improvements in both therapeutic and follow-up strategies are urgently needed. In previous work we described an oscillatory pattern of response to Temozolomide (TMZ) using a standard administration protocol, detected through MRSI-based machine learning approaches. In the present work, we have introduced the Immune-Enhancing Metronomic Schedule (IMS) with an every 6-d TMZ administration at 60 mg/kg and investigated the consistence of such oscillatory behaviour. A total of n = 17 GL261 GB tumour-bearing C57BL/6j mice were studied with MRI/MRSI every 2 d, and the oscillatory behaviour (6.2 ± 1.5 d period from the TMZ administration day) was confirmed during response. Furthermore, IMS-TMZ produced significant improvement in mice survival (22.5 ± 3.0 d for controls vs 135.8 ± 78.2 for TMZ-treated), outperforming standard TMZ treatment. Histopathological correlation was investigated in selected tumour samples (n = 6) analyzing control and responding fields. Significant differences were found for CD3+ cells (lymphocytes, 3.3 ± 2.5 vs 4.8 ± 2.9, respectively) and Iba-1 immunostained area (microglia/macrophages, 16.8% ± 9.7% and 21.9% ± 11.4%, respectively). Unexpectedly, during IMS-TMZ treatment, tumours from some mice (n = 6) fully regressed and remained undetectable without further treatment for 1 mo. These animals were considered "cured" and a GL261 re-challenge experiment performed, with no tumour reappearance in five out of six cases. Heterogeneous therapy response outcomes were detected in tumour-bearing mice, and a selected group was investigated (n = 3 non-responders, n = 6 relapsing tumours, n = 3 controls). PD-L1 content was found ca. 3-fold increased in the relapsing group when comparing with control and non-responding groups, suggesting that increased lymphocyte inhibition could be associated to IMS-TMZ failure. Overall, data suggest that host immune response has a relevant role in therapy response/escape in GL261 tumours under IMS-TMZ therapy. This is associated to changes in the metabolomics pattern, oscillating every 6 d, in agreement with immune cycle length, which is being sampled by MRSI-derived nosological images.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Cancer metabolism in a snapshot, MRS(I)

  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
The contribution of MRS(I) to the in vivo evaluation of cancer-metabolism-derived metrics, mostly since 2016, is reviewed here. Increased carbon consumption by tumour cells, which are highly glycolytic, is now being sampled by 13C magnetic resonance spectroscopic imaging (MRSI) following the injection of hyperpolarized [1-13C] pyruvate (Pyr). Hot-spots of, mostly, increased lactate dehydrogenase activity or flow between Pyr and lactate (Lac) have been seen with cancer progression in prostate (preclinical and in humans), brain and pancreas (both preclinical) tumours. Therapy response is usually signalled by decreased Lac/Pyr 13C-labelled ratio with respect to untreated or non-responding tumour. For therapeutic agents inducing tumour hypoxia, the 13C-labelled Lac/bicarbonate ratio may be a better metric than the Lac/Pyr ratio. 31P MRSI may sample intracellular pH changes from brain tumours (acidification upon antiangiogenic treatment, basification at fast proliferation and relapse). The steady state tumour metabolome pattern is still in use for cancer evaluation. Metrics used for this range from quantification of single oncometabolites (such as 2-hydroxyglutarate in mutant IDH1 glial brain tumours) to selected metabolite ratios (such as total choline to N-acetylaspartate (plain ratio or CNI index)) or the whole 1H MRSI(I) pattern through pattern recognition analysis. These approaches have been applied to address different questions such as tumour subtype definition, following/predicting the response to therapy or defining better resection or radiosurgery limits.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Extraction of artefactual MRS patterns from a large database using non-negative matrix factorization

  • Hernández-Villegas, Yanisleydis|||0000-0002-4309-5113
  • Ortega-Martorell, Sandra|||0000-0001-9927-3209
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Vellido, Alfredo|||0000-0002-9843-1911
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
Despite the success of automated pattern recognition methods in problems of human brain tumor diagnostic classification, limited attention has been paid to the issue of automated data quality assessment in the field of MRS for neuro-oncology. Beyond some early attempts to address this issue, the current standard in practice is MRS quality control through human (expert-based) assessment. One aspect of automatic quality control is the problem of detecting artefacts in MRS data. Artefacts, whose variety has already been reviewed in some detail and some of which may even escape human quality control, have a negative influence in pattern recognition methods attempting to assist tumor characterization. The automatic detection of MRS artefacts should be beneficial for radiology as it guarantees more reliable tumor characterizations, as well as the development of more robust pattern recognition-based tumor classifiers and more trustable MRS data processing and analysis pipelines. Feature extraction methods have previously been used to help distinguishing between good and bad quality spectra to apply subsequent supervised pattern recognition techniques. In this study, we apply feature extraction differently and use a variant of a method for blind source separation, namely Convex Non-Negative Matrix Factorization, to unveil MRS signal sources in a completely unsupervised way. We hypothesize that, while most sources will correspond to the different tumor patterns, some of them will reflect signal artefacts. The experimental work reported in this paper, analyzing a combined short and long echo time 1H-MRS database of more than 2000 spectra acquired at 1.5T and corresponding to different tumor types and other anomalous masses, provides a first proof of concept that points to the possible validity of this approach.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Machine Learning Analysis of Single-Voxel Proton MR Spectroscopy for Differentiating Solitary Fibrous Tumors and Meningiomas

  • Toth, Lili Fanni|||0000-0002-4553-292X
  • Majos, Carles|||0000-0003-0468-5150
  • Pons-Escoda, Albert|||0000-0003-4167-8291
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
Solitary fibrous tumor (SFT), formerly known as hemangiopericytoma, is an uncommon brain tumor often confused with meningioma on MRI. Unlike meningiomas, SFTs exhibit a myoinositol peak on magnetic resonance spectroscopy (MRS). This study aimed to develop automated classifiers to distinguish SFT from meningioma grades using MRS data from a 26-year patient cohort. Four classification tasks were performed on short echo (SE), long echo (LE) time, and concatenated SE + LE spectra, with datasets split into 80% training and 20% testing sets. Sequential forward feature selection and linear discriminant analysis identified features to distinguish between meningioma Grade 1 (Men-1), meningioma grade 2 (Men-2), meningioma grade 3 (Men-3), and SFT (the 4-class classifier); Men-1 from Men-2 + 3 + SFT; meningioma (all) from SFT; and Men-1 from Men-2 + 3 and SFT. The best classifier was defined by the smallest balanced error rate (BER) in the testing phase. A total of 136 SE cases and 149 LE cases were analyzed. The best features in the 4-class classifier were myoinositol and alanine at SE, and myoinositol, glutamate, and glutamine at LE. Myoinositol alone distinguished SFT from meningiomas. Differentiating Men-1 from Men-2 was not possible with MRS, and combining higher meningioma grades did not improve distinction from Men-1. Notably, combining short and long echo times (TE) enhances classification performance, particularly in challenging outlier cases. Furthermore, the robust classifier demonstrates efficacy even when dealing with spectra of suboptimal quality. The resulting classifier is available as Supporting Information of the publication. Extensive documentation is provided, and the software is free and open to all users without a login requirement.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Protein kinase CK2 content in GL261 mouse glioblastoma

  • Ferrer-Font, Laura|||0000-0002-3131-7233
  • Alcaraz Muñoz, Estefania
  • Plana i Coll, Maria|||0000-0001-5808-9229
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Itarte, Emilio|||0000-0002-9366-5807
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
Glioblastoma (GBM) is the most prevalent and aggressive human glial tumour with a median survival of 14-15 months. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment. Unfortunately, chemoresistence always ensues with concomitant tumour regrowth. Protein kinase CK2 (CK2) contributes to tumour development, proliferation, and suppression of apoptosis in cancer and it is overexpressed in human GBM. Targeting CK2 in GBM treatment may benefit patients. With this translational perspective in mind, we have studied the CK2 expression level by Western blot analysis in a preclinical model of GBM: GL261 cells growing orthotopically in C57BL/6 mice. The expression level of the CK2 catalytic subunit (CK2α) was higher in tumour (about 4-fold) and in contralateral brain parenchyma (more than 2-fold) than in normal brain parenchyma (p < 0.05). In contrast, no significant changes were found in CK2 regulatory subunit (CK2β) expression, suggesting an increased unbalance of CK2α/CK2β in GL261 tumours with respect to normal brain parenchyma, in agreement with a differential role of these two subunits in tumours.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of a transplantable glioma tumour model from genetically engineered mice, MRI/MRS/MRSI characterisation

  • Ciezka, Magdalena
  • Acosta González, Milena
  • Herranz, Cristina
  • Canals, Josep M.|||0000-0001-6829-7670
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
The initial aim of this study was to generate a transplantable glial tumour model of low-intermediate grade by disaggregation of a spontaneous tumour mass from genetically engineered models (GEM). This should result in an increased tumour incidence in comparison to GEM animals. An anaplastic oligoastrocytoma (OA) tumour of World Health Organization (WHO) grade III was obtained from a female GEM mouse with the S100β-v-erbB/inK4a-Arf (+/-) genotype maintained in the C57BL/6 background. The tumour tissue was disaggregated; tumour cells from it were grown in aggregates and stereotactically injected into C57BL/6 mice. Tumour development was followed using Magnetic Resonance Imaging (MRI), while changes in the metabolomics pattern of the masses were evaluated by Magnetic Resonance Spectroscopy/Spectroscopic Imaging (MRS/MRSI). Final tumour grade was evaluated by histopathological analysis. The total number of tumours generated from GEM cells from disaggregated tumour (CDT) was 67 with up to 100 % penetrance, as compared to 16 % in the local GEM model, with an average survival time of 66 ± 55 days, up to 4.3-fold significantly higher than the standard GL261 glioblastoma (GBM) tumour model. Tumours produced by transplantation of cells freshly obtained from disaggregated GEM tumour were diagnosed as WHO grade III anaplastic oligodendroglioma (ODG) and OA, while tumours produced from a previously frozen sample were diagnosed as WHO grade IV GBM. We successfully grew CDT and generated tumours from a grade III GEM glial tumour. Freezing and cell culture protocols produced progression to grade IV GBM, which makes the developed transplantable model qualify as potential secondary GBM model in mice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting protein kinase CK2, evaluationg CX-4945 potential for GL261 glioblastoma therapy in immunocompetent mice

  • Ferrer Font, Laura|||0000-0002-3131-7233
  • Villamañan De Santiago, Lucia|||0000-0002-6702-2103
  • Arias Ramos, Nuria|||0000-0001-8983-6362
  • Vilardell Vilà, Jordi
  • Plana i Coll, Maria|||0000-0001-5808-9229
  • Ruzzene, Maria
  • Pinna, Lorenzo A.
  • Itarte, Emilio|||0000-0002-9366-5807
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastoma (GBM) causes poor survival in patients even with aggressive treatment. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment but resistance always ensues. Protein kinase CK2 (CK2) contributes to tumour development and proliferation in cancer, and it is overexpressed in human GBM. Accordingly, targeting CK2 in GBM may benefit patients. Our goal has been to evaluate whether CK2 inhibitors (iCK2s) could increase survival in an immunocompetent preclinical GBM model. Cultured GL261 cells were treated with different iCK2s including CX-4945, and target effects evaluated in vitro. CX-4945 was found to decrease CK2 activity and Akt(S129) phosphorylation in GL261 cells. Longitudinal in vivo studies with CX-4945 alone or in combination with TMZ were performed in tumour-bearing mice. Increase in survival (p < 0.05) was found with combined CX-4945 and TMZ metronomic treatment (54.7 ± 11.9 days, n = 6) when compared to individual metronomic treatments (CX-4945: 24.5 ± 2.0 and TMZ: 38.7 ± 2.7, n = 6) and controls (22.5 ± 1.2, n = 6). Despite this, CX-4945 did not improve mice outcome when administered on every/alternate days, either alone or in combination with 3-cycle TMZ. The highest survival rate was obtained with the metronomic combined TMZ+CX-4945 every 6 days, pointing to the participation of the immune system or other ancillary mechanism in therapy response.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Metabolomics of Therapy Response in Preclinical Glioblastoma, a Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment

  • Arias-Ramos, Nuria|||0000-0001-8983-6362
  • Ferrer-Font, Laura|||0000-0002-3131-7233
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
  • Mocioiu, Victor
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a short survival time even after aggressive therapy. Non-invasive surrogate biomarkers of therapy response may be relevant for improving patient survival. Previous work produced such biomarkers in preclinical GBM using semi-supervised source extraction and single-slice Magnetic Resonance Spectroscopic Imaging (MRSI). Nevertheless, GBMs are heterogeneous and single-slice studies could prevent obtaining relevant information. The purpose of this work was to evaluate whether a multi-slice MRSI approach, acquiring consecutive grids across the tumor, is feasible for preclinical models and may produce additional insight into therapy response. Nosological images were analyzed pixel-by-pixel and a relative responding volume, the Tumor Responding Index (TRI), was defined to quantify response. Heterogeneous response levels were observed and treated animals were ascribed to three arbitrary predefined groups: high response (HR, n = 2), TRI = 68.2 ± 2.8%, intermediate response (IR, n = 6), TRI = 41.1 ± 4.2% and low response (LR, n = 2), TRI = 13.4 ± 14.3%, producing therapy response categorization which had not been fully registered in single-slice studies. Results agreed with the multi-slice approach being feasible and producing an inverse correlation between TRI and Ki67 immunostaining. Additionally, ca. 7-day oscillations of TRI were observed, suggesting that host immune system activation in response to treatment could contribute to the responding patterns detected.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Brain metabolic pattern analysis using a magnetic resonance spectra classification software in experimental stroke

  • Jiménez Xarrié, Elena|||0000-0003-3567-0672
  • Dàvila Huerta, Myriam
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Ortega Martorell, Sandra|||0000-0001-9927-3209
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
Magnetic resonance spectroscopy (MRS) provides non-invasive information about the metabolic pattern of the brain parenchyma in vivo. The SpectraClassifier software performs MRS pattern-recognition by determining the spectral features (metabolites) which can be used objectively to classify spectra. Our aim was to develop an Infarct Evolution Classifier and a Brain Regions Classifier in a rat model of focal ischemic stroke using SpectraClassifier. A total of 164 single-voxel proton spectra obtained with a 7 Tesla magnet at an echo time of 12 ms from non-infarcted parenchyma, subventricular zones and infarcted parenchyma were analyzed with SpectraClassifier (). The spectra corresponded to Sprague-Dawley rats (healthy rats, n = 7) and stroke rats at day 1 post-stroke (acute phase, n = 6 rats) and at days 7 ± 1 post-stroke (subacute phase, n = 14). In the Infarct Evolution Classifier, spectral features contributed by lactate + mobile lipids (1.33 ppm), total creatine (3.05 ppm) and mobile lipids (0.85 ppm) distinguished among non-infarcted parenchyma (100% sensitivity and 100% specificity), acute phase of infarct (100% sensitivity and 95% specificity) and subacute phase of infarct (78% sensitivity and 100% specificity). In the Brain Regions Classifier, spectral features contributed by myoinositol (3.62 ppm) and total creatine (3.04/3.05 ppm) distinguished among infarcted parenchyma (100% sensitivity and 98% specificity), non-infarcted parenchyma (84% sensitivity and 84% specificity) and subventricular zones (76% sensitivity and 93% specificity). SpectraClassifier identified candidate biomarkers for infarct evolution (mobile lipids accumulation) and different brain regions (myoinositol content). The online version of this article (doi:10.1186/s12868-016-0328-x) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Anti-PD-1 immunotherapy in preclinical GL261 glioblastoma, influence of therapeutic parameters and noninvasive response biomarker assessment with MRSI-based approaches

  • Wu, Shuang|||0000-0001-7618-5476
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastomas (GBs) are malignant brain tumours with poor prognosis even after aggressive therapy. Programmed cell death-1 (PD-1) immune checkpoint blockade is a promising strategy in many types of cancer, but its therapeutic effects in GB remain low and associated with immune infiltration. Previous work suggests that oscillations of magnetic resonance spectroscopic imaging (MRSI)-based response pattern with chemotherapy could act as a biomarker of efficient immune system attack onto GBs. The presence of such oscillations with other monotherapies such as anti-PD-1 would reinforce its monitoring potential. Here, we confirm that the oscillatory behaviour of the response biomarker is also detected in mice treated with anti PD-1 immunotherapy both in combination with temozolomide and as monotherapy. This indicates that the spectral pattern changes observed during therapy response are shared by different therapeutic strategies, provided the host immune system is elicited and able to productively attack tumour cells. Moreover, the participation of the immune system in response is also supported by the rate of cured animals observed with different therapeutic strategies (in the range of 50-100% depending on the treatment), which also held long-term immune memory against tumour cells re-challenge. Taken together, our findings open the way for a translational use of the MRSI-based biomarker in patient-tailored GB therapy, including immunotherapy, for which reliable non-invasive biomarkers are still missing.
Dipòsit Digital de Documents de la UAB
Research data Set de datos (Dataset)

qPCR values of control and TMZ-treated GL261 GB samples

  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Wu, Shuang|||0000-0001-7618-5476
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
This dataset is composed by 20 GL261 GB samples, n=10 from control mice and n=10 of IMS-TMZ treated, responding mice. Samples were extracted and analyzed by qPCR for gene expression levels related to macrophage polarization (Nos2 and CD206), programmed cell death-1 ligand-1 expression (PDL1), as well as 2 housekeeping genes for normalization.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune system-related changes in preclinical GL261 glioblastoma under TMZ treatment, Explaining MRSI-based nosological imaging findings with RT-PCR analyses

  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Wu, Shuang|||0000-0001-7618-5476
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy. Previous work suggests that magnetic resonance spectroscopic imaging (MRSI) could act as a biomarker of efficient immune system attack onto GB, presenting oscillatory changes. Glioma-associated microglia/macrophages (GAMs) constitute the most abundant non-tumour cell type within the GB and can be polarised into anti-tumour (M1) or pro-tumour (M2) phenotypes. One of the mechanisms to mediate immunosuppression in brain tumours is the interaction between programmed cell death-1 ligand 1 (PD-L1) and programmed cell death-1 receptor (PD-1). We evaluated the subpopulations of GAMs in responding and control GB tumours to correlate PD-L1 expression to GAM polarisation in order to explain/validate MRSI-detected findings. Mice were evaluated by MRI/MRSI to assess the extent of response to treatment and with qPCR for GAMs M1 and M2 polarisation analyses. M1/M2 ratios and PD-L1 expression were higher in treated compared to control tumours. Furthermore, PD-L1 expression was positively correlated with the M1/M2 ratio. The oscillatory change in the GAMs prevailing population could be one of the key causes for the differential MRSI-detected pattern, allowing this to act as immune system activity biomarker in future work.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Using Single-Voxel Magnetic Resonance Spectroscopy Data Acquired at 1.5T to Classify Multivoxel Data at 3T, A Proof-of-Concept Study

  • Ungan, Gulnur Semahat|||0000-0002-5436-4665
  • Pons-Escoda, Albert|||0000-0003-4167-8291
  • Ulinic, Daniel|||0009-0006-3318-0839
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Vellido, Alfredo|||0000-0002-9843-1911
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
In vivo magnetic resonance spectroscopy (MRS) has two modalities, single-voxel (SV) and multivoxel (MV), in which one or more contiguous grids of SVs are acquired. Purpose: To test whether MV grids can be classified with models trained with SV. Methods: Retrospective study. Training dataset: Multicenter multiformat SV INTERPRET, 1.5T. Testing dataset: MV eTumour, 3T. Two classification tasks were completed: 3-class (meningioma vs. aggressive vs. normal) and 4-class (meningioma vs. low-grade glioma vs. aggressive vs. normal). Five different methods were tested for feature selection. The classification was implemented using linear discriminant analysis (LDA), random forest, and support vector machines. The evaluation was completed with balanced error rate (BER) and area under the curve (AUC) on both sets. The accuracy in class prediction was calculated by developing a solid tumor index (STI) and segmentation accuracy with the Dice score. Results: The best method was sequential forward feature selection combined with LDA, with AUCs = 0.95 (meningioma), 0.89 (aggressive), 0.82 (low-grade glioma), and 0.82 (normal). STI was 66% (4-class task) and 71% (3-class task) because two cases failed completely and two more had suboptimal STI as defined by us. Discussion: The reasons for failure in the classification of the MV test set were related to the presence of artifacts.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A comparison of non-negative matrix underapproximation methods for the decomposition of magnetic resonance spectroscopy data from human brain tumors

  • Ungan, Gulnur Semahat|||0000-0002-5436-4665
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Vellido, Alfredo|||0000-0002-9843-1911
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
Magnetic resonance spectroscopy (MRS) is an MR technique that provides information about the biochemistry of tissues in a noninvasive way. MRS has been widely used for the study of brain tumors, both preoperatively and during follow-up. In this study, we investigated the performance of a range of variants of unsupervised matrix factorization methods of the non-negative matrix underapproximation (NMU) family, namely, sparse NMU, global NMU, and recursive NMU, and compared them with convex non-negative matrix factorization (C-NMF), which has previously shown a good performance on brain tumor diagnostic support problems using MRS data. The purpose of the investigation was 2-fold: first, to ascertain the differences among the sources extracted by these methods; and second, to compare the influence of each method in the diagnostic accuracy of the classification of brain tumors, using them as feature extractors. We discovered that, first, NMU variants found meaningful sources in terms of biological interpretability, but representing parts of the spectrum, in contrast to C-NMF; and second, that NMU methods achieved better classification accuracy than C-NMF for the classification tasks when one class was not meningioma.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous

  • Ungan, Gulnur Semahat|||0000-0002-5436-4665
  • Pons-Escoda, Albert|||0000-0003-4167-8291
  • Ulinic, Daniel|||0009-0006-3318-0839
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Ortega-Martorell, Sandra|||0000-0001-9927-3209
  • Olier, Iván|||0000-0002-5679-7501
  • Vellido, Alfredo|||0000-0002-9843-1911
  • Majos, Carles|||0000-0003-0468-5150
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow-up study to evaluate treatment response is performed 1 month after concomitant treatment, when contrast-enhancing regions may appear that can correspond to true progression or pseudoprogression. We retrospectively evaluated 31 consecutive patients at the first follow-up after concomitant treatment to check whether the metabolic pattern assessed with multivoxel MRS was predictive of treatment response 2 months later. We extracted the underlying metabolic patterns of the contrast-enhancing regions with a blind-source separation method and mapped them over the reference images. Pattern heterogeneity was calculated using entropy, and association between patterns and outcomes was measured with Cramér's V. We identified three distinct metabolic patterns-proliferative, necrotic, and responsive, which were associated with status 2 months later. Individually, 70% of the patients showed metabolically heterogeneous patterns in the contrast-enhancing regions. Metabolic heterogeneity was not related to the regions' size and only stable patients were less heterogeneous than the rest. Contrast-enhancing regions are also metabolically heterogeneous 1 month after concomitant treatment. This could explain the reported difficulty in finding robust pseudoprogression biomarkers.